Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Bristol-Myers, Meso Scale To Develop Diagnostic Assays For Alzheimer's Disease

Bristol-Myers Squibb Co. (BMY: Quote) and Meso Scale Discovery announced they have entered an agreement to develop diagnostic assays that will measure cerebrospinal fluid biomarkers for use in Alzheimer's disease research.

As per the terms of the agreement, the companies will develop these assays based on the Meso Scale Discovery MULTI-ARRAY technology platform. Meso Scale Discovery will commercialize the assays for Alzheimer's disease research and drug development, and plans to release the assays in the second quarter of 2012. Terms of the agreement were not disclosed.

Alzheimer's disease is a progressive brain disease that impairs memory, interferes with thinking and ultimately destroys the ability of an individual to carry out simple tasks. The disease is a continuum, with damage to the brain starting long before the onset of dementia.

Click here to receive FREE breaking news email alerts for Bristol-Myers Squibb Co. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After ending the previous session nearly flat, stocks moved mostly lower over the course of the trading day on Friday. Uncertainty about the outlook for monetary policy weighed on the markets ahead of next week's Federal Reserve meeting. Despite the ceasefire in eastern Ukraine, the U.S. Treasury Department on Friday announced a new round of sanctions against Russia for its role in the conflict. Treasury Secretary Jacob Lew determined that persons operating within Russia's defense and related materiel sector may now be subject to targeted sanctions. Business inventories in the U.S increased in line with economist estimates in the month of July, according to a report released by the Commerce Department on Friday. The Commerce Department said business inventories rose by 0.4 percent in July, matching the increase reported for June as well as the consensus estimate.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.